Spyre Therapeutics Inc. (SYRE)
Healthcare
Biotechnology
98.30 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Spyre Therapeutics Inc. (SYRE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.3% of the shares are freely tradable; institutional investors hold 93.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
93.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
5.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
93.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
15.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
87Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.57 | 11,781,024 | +1.2 | 03/31/2026 |
| BlackRock Inc | 6.36 | 5,521,221 | +0.0 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 4.80 | 4,171,996 | +0.0 | 03/31/2026 |
| Fairmount Funds Management LLC | 4.63 | 4,018,101 | +0.0 | 03/31/2026 |
| Perceptive Advisors LLC | 4.36 | 3,783,225 | +23.3 | 03/31/2026 |
| VR Adviser, LLC | 4.24 | 3,685,448 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.52 | 3,057,401 | +0.0 | 03/31/2026 |
| Driehaus Capital Management LLC | 3.21 | 2,790,785 | -3.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 4.11 | 3,565,845 | +5.3 | 05/31/2026 |
| Fidelity Growth Company Fund | 3.06 | 2,661,379 | +3.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.